Novo Nordisk’s latest STEER study, unveiled at the European Society of Cardiology Congress 2025 in Madrid, shows Wegovy® (semaglutide 2.4 mg) delivering stronger cardiovascular protection than tirzepatide. For people living with obesity and heart disease, the results could be a game-changer.
Here are eight insights you need to know:
1. A 57% lower risk of heart attack, stroke or death
In patients who stayed on continuous therapy, Wegovy slashed major cardiovascular risks by 57% compared with tirzepatide.
2. Even with treatment gaps, Wegovy leads
Across all patients, including those who missed doses, Wegovy still showed a 29% reduction in serious heart-related events.
3. Dramatic difference in recorded events
Only 15 cardiovascular incidents (0.1%) occurred in Wegovy patients versus 39 cases (0.4%) in the tirzepatide group.
4. Strong evidence across studies
These results add to Novo Nordisk’s SELECT and SCORE trials, both of which confirmed Wegovy’s heart-protective effects.
5. Benefits are molecule-specific
Experts stress that semaglutide’s unique properties deliver these results, meaning other GLP-1 or GIP/GLP-1 drugs should not be assumed to have the same impact.
6. Obesity’s deadly link to CVD
Obesity drives millions of cardiovascular deaths annually, with two out of three obesity-related deaths tied to heart disease.
7. Real-world data adds credibility
Unlike controlled trials, the STEER study analyzed patient experiences in everyday clinical settings, reinforcing Wegovy’s effectiveness outside the lab.
8. Wegovy positioned as the gold standard
With consistent outcomes across trials and real-world studies, Wegovy now stands out as the leading obesity treatment with proven heart health benefits.
Novo Nordisk’s findings could redefine treatment strategies for obesity and cardiovascular disease, making Wegovy more than just a weight-loss drug but a life-saving therapy.
